Further, since AHRR methylation only reverts very slowly over decades after smoking cessation [6], the prognostic benefit from quitting within years before blood sampling, cannot be monitored by measuring AHRR methylation, especially in cohorts with poor short-term prognosis, i.e. lung cancer patients. The gene discussed is AHRR; the disease is lung cancer.